Safety of recombinant human growth hormone in treating children with growth hormone deficiency and idiopathic short stature

Acta Academiae Medicinae Sinicae

Volumn 33, Issue 2, 2011, Pages 123-126

  Shu, Chang ^a   Pan, Hui ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

Adverse drug reactions; Growth hormone deficiency; Idiopathic short stature; Recombinant human growth hormone

Indexed keywords

HUMAN GROWTH HORMONE;

ARTICLE; BRAIN PSEUDOTUMOR; CHILDHOOD DISEASE; DRUG SAFETY; GROWTH HORMONE DEFICIENCY; HUMAN; IDIOPATHIC DISEASE; INCIDENCE; INSULIN SENSITIVITY; METASTASIS; SCOLIOSIS; SHORT STATURE; SIDE EFFECT; SLIPPED CAPITAL FEMORAL EPIPHYSIS; SODIUM RETENTION; WATER RETENTION;

DWARFISM; DWARFISM, PITUITARY; HUMAN GROWTH HORMONE; HUMANS; RECOMBINANT PROTEINS;

EID: 79957541528     PISSN: 1000503X     EISSN: None     Source Type: Journal    
DOI: 10.3881/j.issn.1000-503X.2011.02.005     Document Type: Article

References (15)

1. Clayton PE, Cowell CT. Safety issues in children and adolescents during growth hormone therapy-a review [J]. Growth Horm IGF Res, 2000, 10(6): 306-317. (Pubitemid 32125101)
2. Burgert TS, Vuguin PM, DiMartino-Nardi J, et al. Assessing insulin resistance: application of a fasting glucose to insulin ratio in growth hormone-treated children [J]. Horm Res, 2002, 57(1-2): 37-42. (Pubitemid 34518757)
3. Quigley CA, Gill AM, Crowe BJ, et al. Safety of growth hormone treatment in pediatric patients with idiopathic short stature [J]. J Clin Endocrinol Metab, 2005, 90(9): 5188-5196.
4. Blethen SL, Allen DB, Graves D, et al. Safety of recombinant deoxyribonucleic acid-derived growth hormone: the National Cooperative Growth Study experience [J]. J Clin Endocrinol Metab, 1996, 81(5): 1704-1710. (Pubitemid 26152449)
5. Cowell CT, Dietsch S. Adverse events during growth hormone therapy [J]. J Pediatr Endocrinol Metab, 1995, 8(4): 243-252. (Pubitemid 26021307)
6. Cutfield WS, Wilton P, Bennmarker H, et al. Incidence of diabetes mellitus and impaired glucose tolerance in children and adolescents receiving growth-hormone treatment [J]. Lancet, 2000, 355(9204): 610-613.
7. Wilton P. Adverse events during GH treatment: 10 years' experience in KIGS, a pharmacoepidemiological survey [M] //Ranke MB, Wilton P, eds. Progress in growth hormone therapy-10 years of KIGS. Leipzig; Barth, 1999: 349-364.
8. Shalet SM, Brennen BM, Reddingius RE. Growth hormone therapy and malignancy [J]. Horm Res, 1997, 48(Suppl 4): 29-32.
9. Allen DB, Rundle AC, Graves DA, et al. Risk of leukemia in children treated with human growth hormone: review and reanalysis [J]. J Pediatr, 1997, 131(1 Pt 2): S32-S36. (Pubitemid 27505695)
10. Swerdlow AJ, Higgins CD, Adlard P, et al. Risk of cancer in patients treated with human pituitary growth hormone in the UK, 1959-85: a cohort study [J]. Lancet, 2002, 360(9329): 273-277.
11. Tuffli GA, Johanson A, Rundle AC, et al. Lack of increased risk for extracranial, nonleukemic neoplasms in recipients of recombinant deoxyribonucleic acid growth hormone [J]. J Clin Endocrinol Metab, 1995, 80(4): 1416-1422.
12. Darendeliler F, Karagiannis G, Wilton P, et al. Recurrence of brain tumours in patients treated with growth hormone: analysis of KIGS (Pfizer International Growth Database) [J]. Acta Paediatr, 2006, 95(10): 1284-1290. (Pubitemid 44423196)
13. Bell J, Parker KL, Swinford RD, et al. Long-term safety of recombinant human growth hormone in children [J]. J Clin Endocrinol Metab, 2010, 95(1): 167-177.
14. Sklar CA, Mertens AC, Mitby P, et al. Risk of disease recurrence and second neoplasms in survivors of childhood cancer treated with growth hormone: a report from the Childhood Cancer Survivor Study [J]. J Clin Endocrinol Metab, 2002, 87(7): 3136-3141. (Pubitemid 34816355)